Cardiovascular

Latest News

Teenage boy getting blood pressure checked | Image Credit: Halfpoint - stock.adobe.com
Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

July 28th 2025

This global study found rising rates of pediatric hypertension, highlighting obesity's impact and the need for improved monitoring and prevention strategies.

Eliquis packaging | Image credit: Semi – stock.adobe.com
Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

July 17th 2025

Blood pressure monitor on patient's arm | Image credit: CasanoWa Stutio – stock.adobe.com
Delayed Hypertension Diagnosis Tied to Higher Cardiovascular Risk, Lower Treatment Rates

July 14th 2025

Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com
40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

June 19th 2025

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease
Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

June 3rd 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Continuing Medical Education
View All
August 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 3rd 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
August 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 3rd 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
August 3rd 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
August 3rd 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Cardiac graphic
November 17th 2020

Study Highlights Finerenone Benefits in CV Outcomes for Patients With CKD

Allison Inserro
Finerenone may represent an important step forward to reducing cardiac illness and death in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the study said.
Lincoff
November 15th 2020

Fish Oil Debate Continues as Study Finds No Risk Reduction From Omega-3 Combo

Mary Caffrey
The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.
Site Logo
November 10th 2020

AHA Telemetry Guidelines Improve Telemetry Utilization in the Inpatient Setting

Sima S. Pendharkar, MD, MPH Ibrahim B. Barry, MD, MPH Saikrishna Patibandla, MD, MS Tiffany I. Leung, MD, MPH Amol Gupta, MBBS Aung Naing Lin, MD James A. Gasperino, MD, PhD, MPH
Using Plan-Do-Study-Act cycles, the studied intervention reduced hospital inpatient telemetry time by 51.25% while increasing American Heart Association (AHA) guideline–based usage.
Site Logo
November 10th 2020

Telemetry: Appropriateness of Initial Assignment and Duration in Nonintensive Setting

Rohit Chaudhary, MIS Thomas Kingsley, MD Sauradeep Sarkar, MD Joseph Carrington, DO Galo M. Sanchez Palacios, MD Tushar Sharma, MD Jalaj Garg, MD Rahul Chaudhary, MD, MBA
The authors report overutilization of telemetry monitoring in a community setting, increasing the cost of health care and potential harm to patients with unnecessary interventions.
Site Logo
October 19th 2020

Social Determinants of Health Score: Does It Help Identify Those at Higher Cardiovascular Risk?

Ana Palacio, MD, MPH Ruaa Mansi, MD, MPH David Seo, MD Maritza Suarez, MD Sylvia Garay, MD Heidy Medina, MPH Fei Tang, PhD Leonardo Tamariz, MD, MPH
Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.
Better Strategies to Reduce Cardiovascular Events
September 16th 2020

Better Strategies to Reduce Cardiovascular Events

Clinical Pathways for Cardiovascular Disease Management
September 16th 2020

Clinical Pathways for Cardiovascular Disease Management

CVD: Cost-Effectiveness Data and Treatment Selection
September 16th 2020

CVD: Cost-Effectiveness Data and Treatment Selection

Cost-Effectiveness Data and Pricing of Icosapent Ethyl
September 16th 2020

Cost-Effectiveness Data and Pricing of Icosapent Ethyl

CV Risk Reduction and Coverage of Therapies
September 16th 2020

CV Risk Reduction and Coverage of Therapies

Cardiovascular Disease Treatment Decisions and Cost
September 16th 2020

Cardiovascular Disease Treatment Decisions and Cost

Cost-Effectiveness and Cardiovascular Risk
September 16th 2020

Cost-Effectiveness and Cardiovascular Risk

Implications for Treating Patients With Icosapent Ethyl
September 16th 2020

Implications for Treating Patients With Icosapent Ethyl

Coronary Plaque Regression and CV Risk
September 16th 2020

Coronary Plaque Regression and CV Risk

Interim Analysis of EVAPORATE
September 16th 2020

Interim Analysis of EVAPORATE

The REDUCE-IT Study and CV Risk
September 16th 2020

The REDUCE-IT Study and CV Risk

Targeting Triglycerides to Reduce CV Risk
September 16th 2020

Targeting Triglycerides to Reduce CV Risk

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
September 16th 2020

Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors

PCSK9 Inhibitors and CV Risk
September 16th 2020

PCSK9 Inhibitors and CV Risk

Statin Therapy: Risk for Future CV Events
September 16th 2020

Statin Therapy: Risk for Future CV Events

Statin Therapy for LDL Reduction and CV Risk
September 16th 2020

Statin Therapy for LDL Reduction and CV Risk

Dyslipidemia: Strategies Used to Reduce CV Risk
September 16th 2020

Dyslipidemia: Strategies Used to Reduce CV Risk

Cardiovascular Risk Management
September 16th 2020

Cardiovascular Risk Management

LDL Cholesterol Lowering and CV Risk
September 16th 2020

LDL Cholesterol Lowering and CV Risk

Risk Assessment for Cardiovascular Disease
September 16th 2020

Risk Assessment for Cardiovascular Disease

Economic Burden of Cardiovascular Disease
September 16th 2020

Economic Burden of Cardiovascular Disease

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show
July 25th 2020

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show

Mary Caffrey
Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning
Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone
July 17th 2020

Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone

Mary Caffrey
Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.
Site Logo
June 16th 2020

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure

Mary Caffrey
A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.
Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D
June 16th 2020

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.
<1
...
456789101112
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo